Shockwave Therapy for Chronic Knee Pain
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to test a new treatment for chronic knee pain caused by bone marrow lesions (BMLs) in osteoarthritis patients. It compares focused extracorporeal shockwave therapy, a non-invasive treatment using sound waves, to standard care such as painkillers and limited movement. The goal is to determine if this new method can safely reduce pain and improve knee function more effectively than usual treatments. Individuals who continue to experience knee pain after at least four weeks of conservative treatment might be suitable candidates for this trial. As an unphased trial, it offers patients the opportunity to explore innovative treatments that could potentially enhance their quality of life.
Do I have to stop taking my current medications for the trial?
The trial protocol does not specify if you need to stop all current medications. However, if you have used bisphosphonates, there is a required washout period based on how long you used them. Also, you cannot participate if you are currently receiving glucocorticoids or have had an intra-articular steroid injection in the last 3 months.
What prior data suggests that this shockwave therapy is safe for treating knee pain?
Research has shown that focused extracorporeal shockwave therapy (f-ESWT) is generally safe and well-tolerated for treating knee problems. In various studies, patients reported less pain and improved knee function within 12 weeks of treatment. This therapy has been used for different bone and ligament issues, aiding in pain relief and healing without major side effects.
Previous findings indicate that f-ESWT is a non-invasive treatment, meaning it doesn't involve surgery or other procedures that enter the body. This makes it an appealing option for people with knee osteoarthritis, as it avoids the risks associated with more invasive treatments. Overall, existing evidence supports the safety of f-ESWT for similar conditions, suggesting it is a promising choice for managing knee pain.12345Why are researchers excited about this trial?
Focused Extracorporeal Shockwave Therapy (ESWT) is unique because it offers a non-invasive approach to treating chronic knee pain, unlike the standard options like pain relievers, physical therapy, or surgeries. This therapy uses pressure waves to stimulate healing in the affected area, potentially enhancing tissue repair and reducing inflammation. Researchers are excited about ESWT because it targets the knee pain directly and could provide relief without the need for medication or invasive procedures. Additionally, its promise of fewer side effects and quicker recovery makes it a compelling option for those suffering from chronic knee pain.
What evidence suggests that focused extracorporeal shockwave therapy is effective for chronic knee pain?
Studies have shown that focused extracorporeal shockwave therapy (f-ESWT), which participants in this trial will receive, can reduce pain and improve knee function in people with knee osteoarthritis (OA). Research suggests that this therapy decreases knee swelling and enhances overall movement. One study found that f-ESWT relieves pain and aids physical activities more effectively than some other types of shockwave therapy. Another review concluded that higher energy levels in the treatment can lead to better results. Overall, these findings suggest that f-ESWT could be a promising option for those with painful knee OA.16789
Are You a Good Fit for This Trial?
This trial is for men and women aged 30-80 with knee pain from osteoarthritis, confirmed by MRI to have bone marrow lesions. They should have tried conservative treatments like rest and analgesics for at least 4 weeks without success. People with severe coagulopathy, tumors in the treatment area, recent knee surgery or injections, metal implants incompatible with MRI, pregnancy, or autoimmune diseases cannot participate.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either focused extracorporeal shockwave therapy (f-ESWT) or standard of care treatment over 4 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment, with assessments at 1, 2, 3, and 6 months
What Are the Treatments Tested in This Trial?
Interventions
- Focused Extracorporeal Shockwave Therapy
Focused Extracorporeal Shockwave Therapy is already approved in European Union, United States, Canada, China for the following indications:
- Knee osteoarthritis
- Subchondral bone marrow lesions
- Knee osteoarthritis
- Subchondral bone marrow lesions
- Knee osteoarthritis
- Subchondral bone marrow lesions
- Knee osteoarthritis
- Subchondral bone marrow lesions
Find a Clinic Near You
Who Is Running the Clinical Trial?
Kessler Foundation
Lead Sponsor
New Jersey Regenerative Institute, LLC
Industry Sponsor